Sanyou Biopharmaceuticals, a Shanghai, China-based antibody drug discovery company, raised a Series B funding round of undisclosed amount.
The round was led by LH Ventures and Montesy Investment, with participation from Grand Mount Capital and Seeking Capital. In conjunction with the funding, Zhiyin Lan, venture partner of LH Ventures, will join the Board of Directors of Sanyou Bio.
The company intends to use the funds to expand operations and its business reach.
Established in 2015 and led by Dr. David (Guojun) Lang, CEO, Sanyou Biopharmaceutical is an antibody drug discovery company that focuses on R&D of innovative antibody drugs. The company has been continuously building a high-throughput integrated R&D platform for innovative antibody drugs, collecting technical resources to establish a large antibody library.
The company has established an integrated R&D platform for innovative antibody drug discovery, provided hundreds of R&D solutions and technical services for innovative antibody drug discovery projects to more than 150 pharmaceutical companies and drug development institutions around the world, and carried out more than 10 collaborative R&D projects with more than 10 partners.
Sanyou Bio has established an integrated innovative antibody drug R&D laboratory of several thousand square meters with advanced facilities in “Shanghai Caohejing Hi-Tech Park”. There are 10 major functional modules and more than 40 core technological platforms which are characterized by a series of sub-Trillion phage display antibody libraries, covering innovative antibody drug discovery, antibody engineering, in vitro and in vivo efficacy screening, antibody drug developability analysis, construction of cell lines for production, and manufacturing process development, etc.